News
Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™ Denali Therapeutics Inc. Tue, Feb 1, 2022, 9:00 AM ...
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ ...
Breaking Down Barriers to Access: Lessons Learned From a Successful Stroke Interventional Program. Presenter: Phil Taussky. September 16, 2022. REGISTER for free or LOG IN to view this content. ...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback